Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00857805 · ClinicalTrials.gov registry record · NA
Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma
A NA study, sponsored by Loma Linda University.
- Completed
- Registry status
- NA
- Development phase
- 76
- Enrollment target
NCT00857805 is a NA study that has completed, run by Loma Linda University. The registered enrollment target is 76 participants.
The verdict
NCT00857805, a NA study, has completed, sponsored by Loma Linda University.
- COMPLETED
- Registry status
- NA
- Development phase
- 76 participants
- Enrollment target
Study Summary
Patients with liver tumor burden that exceeds Milan criteria are considered to receive one of the following locoregional treatments: transarterial chemoembolization (TACE), radiofrequency ablation (RFA), percutaneous ethanol injection and proton beam radiation (PBR). The goals of these treatments are to control tumor growth, to downstage tumor size to meet Milan criteria, and to improve survival. Patients who exceed the Milan criteria benefit from tumor downstaging as a result of treatment. Patients who meet Milan criteria benefit from tumor control to bridge them to liver transplantation. TACE is considered the most common locoregional treatment that is used to treat hepatocellular carcinoma (HCC). Proton beam radiotherapy has been used in treating HCC in a few centers across the globe. Phase I and II trials showed a satisfactory safety and efficacy results. Loma Linda University Medical Center is one of these pioneering centers that use proton beam as a treatment for HCC. This is the first randomized trial in the medical field that will compare head-to-head the efficacy of TACE versus proton beam in treating HCC patients.
Interventions
- PROCEDURE Transarterial Chemoembolization
- RADIATION Proton Beam Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2009-01-07 |
| Est. Completion | 2021-07-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00857805
The ClinicalTrials.gov registry entry for NCT00857805 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Transarterial Chemoembolization is the first listed.
NCT00857805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00857805 about?
NCT00857805 is a clinical study titled "Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma". Patients with liver tumor burden that exceeds Milan criteria are considered to receive one of the following locoregional treatments: transarterial chemoembolization (TACE), radiofrequency ablation (RFA), percutaneous ethanol injection and proton beam radiation (PBR). The goals of these treatments ar...
What is the current status of trial NCT00857805?
This trial is currently completed. It is a NA study. The enrollment target is 76 participants. The study started on 2009-01-07. Estimated completion is 2021-07-07.
What interventions are being tested in trial NCT00857805?
The interventions under investigation include: Transarterial Chemoembolization (PROCEDURE), Proton Beam Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT00857805?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.